Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD


Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade

See more here:
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Related Posts